10:22 AM EST, 02/26/2025 (MT Newswires) -- Assembly Biosciences ( ASMB ) shares were higher Wednesday morning after the company said that a first subject has been dosed in the phase 1a trial of ABI-6250, its hepatitis delta virus entry inhibitor candidate.

The study aims to evaluate the safety, tolerability and pharmacokinetics of the therapy across single and multiple ascending dose cohorts in participants. The study will also look at serum bile acids as a biomarker of ABI-6250's engagement of its target, which is the transporter used by the disease to infect hepatocyte.

The company said it expects to share data from the study in Q3.

Price: 12.90, Change: +0.56, Percent Change: +4.54